Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 0.45 |
| ▸ | MIF | P14174 | 4/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | BACH1 | O14867 | 2/20 | 0.41 |
| ▸ | MAFK | O60675 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27575394 | 0.92 | TRPA1 (0.48) | TRPA1MIFNAAAKEAP1NFE2L2 | |
| SCHEMBL27593694 | 0.92 | TRPA1 (0.48) | TRPA1MIFNAAAKEAP1NFE2L2 | |
| SCHEMBL18581783 | 0.92 | TRPA1 (0.48) | TRPA1MIFNAAAKEAP1NFE2L2 | |
| SCHEMBL27593695 | 0.92 | TRPA1 (0.48) | TRPA1MIFNAAAKEAP1NFE2L2 | |
| SCHEMBL27521725 | 0.92 | TRPA1 (0.48) | TRPA1MIFNAAAKEAP1NFE2L2 | |
| SCHEMBL691779 | 0.88 | — | — | |
| SCHEMBL25332582 | 0.77 | — | — | |
| SCHEMBL27976500 | 0.74 | — | — | |
| SCHEMBL27603964 | 0.74 | — | — | |
| SCHEMBL362346 | 0.71 | KEAP1 (0.50) | TRPA1MIFNAAAKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1649574-A | Compositions comprising lycopene for the treatment and prevention of angiogenesis-related pathologies | DSM IP ASSETS BV (NL) | 2005-08-03 | — | — | CN | claimed |
| US-10925304-B2 | Method for treating chronic fatigue syndrome, idiopathic chronic fatigue, and fibromyalgia | PRODUCTIVE AGING LABORATORY, CO., LTD. (JP) | 2021-02-23 | — | — | US | disclosed |
| US-20190343161-A1 | THERAPEUTIC AGENT FOR CHRONIC FATIGUE SYNDROME | PRODUCTIVE AGING LABORATORY, CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| CN-104388487-B | A kind of method that utilization rocket salad glycosides prepares sulforaphane | 北京化工大学 | 2017-07-11 | — | — | CN | disclosed |
| CN-104388487-A | Method for preparing sulforaphane by using roquette seed glycosides | UNIV BEIJING CHEMICAL | 2015-03-04 | — | — | CN | disclosed |
| CN-101631865-A | Flavin monooxygenase and transcription factor involved in glucosinolate biosynthesis | UNIV COPENHAGEN | 2010-01-20 | — | — | CN | disclosed |
| CN-100522154-C | Application of isothiocyanate compounds in preparation of drugs for treating helicobacter infection | JED W FAHEY (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-1272443-C | Method for preparing isothiocyanic ester from cruciferae plants | NEW FUNCTIONAL FOOD DEV TECHNO (JP) | 2006-08-30 | — | — | CN | disclosed |
| CN-1649574-A | Compositions comprising lycopene for the treatment and prevention of angiogenesis-related pathologies | DSM IP ASSETS BV (NL) | 2005-08-03 | — | — | CN | disclosed |
| CN-1469711-A | Treatment of helicobacter with isothiocyanates | W | 2004-01-21 | — | — | CN | disclosed |
| CN-1405316-A | Method for preparing isothiocyanic ester from cruciferae plants | NEW FUNCTIONAL FOOD DEV TECHNO (JP) | 2003-03-26 | — | — | CN | disclosed |
| EP-1069819-A1 | METHOD FOR SELECTIVE INCREASE OF THE ANTICARCINOGENIC GLUCOSINOLATES IN $i(BRASSICA SP.) | Plant Bioscience Limited (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052345-A1 | METHOD FOR SELECTIVE INCREASE OF THE ANTICARCINOGENIC GLUCOSINOLATES IN $i(BRASSICA SP.) | PLANT BIOSCIENCE LIMITED (GB) | 1999-10-21 | — | — | WO | disclosed |